Gholam Reza Berenji

Abstract 4367053: 18 F-FDG PET/CT Evaluation of Incidental Extracardiac CT Findings on 82 Rb-Chloride PET Myocardial Perfusion Imaging

Jasmeet Dhaliwal, Sthuthi David, Cesar Puente, M Nandakumar et autres

Background: Positron emission tomography (PET) combined with computed tomography (CT) is a valuable strategy for myocardial perfusion imaging (MPI) in ischemic heart disease evaluation. CT attenuation correction (CTAC) enhances the diagnostic performance of PET and provides further characterization of the coronary vasculature. …

us (code pays fourni par la source)

Trial in Progress: Randomized Phase II Trial of Targeted Radiation with No Castration for Treatment of Metastatic Castration-Resistant Prostate Cancer

Sara Ebrahimi, Gholam Reza Berenji, M. Rettig, Nicholas George Nickols

Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen–defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

John N. Nikitas, Matthew B. Rettig, Robert Evan Reiter, Alan Lee et autres

us (code pays fourni par la source)

Early detection of recurrent prostate cancer using 18F-DCFPyL PET/CT PET/CT in patients with minimal PSA levels.

Ida Sonni, Nicholas George Nickols, Katelyn Niknam, Gholam Reza Berenji et autres

344 Background: PSMA PET imaging is a highly sensitive and specific imaging tool for detecting prostate cancer, especially in biochemical recurrence (BCR). This has led to growing interest in utilizing PSMA PET for patients with minimally detectable PSA levels following definitive treatment …

us, se (code pays fourni par la source)

Comparing progression following systemic and tumor-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer: A pooled analysis of SOLAR and SATURN clinical trials.

John N. Nikitas, Matthew B. Rettig, Robert Evan Reiter, Alan Lee et autres

64 Background: Therapeutic strategies for oligometastatic castration sensitive prostate cancer (omCSPC) combining treatment of the primary and metastases with short-term intensified systemic therapy aim to improve survival and local control while minimizing toxicity from indefinite systemic therapy. This post-hoc analysis of the …

us (code pays fourni par la source)

Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

Cecil Mayra Benitez, Hannicka Sahlstedt, Ida Sonni, Johan Brynolfsson et autres

BACKGROUND AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) molecular imaging is widely used for disease assessment in prostate cancer (PC). Artificial intelligence (AI) platforms such as automated Prostate Cancer Molecular Imaging Standardized Evaluation (aPROMISE) identify and quantify locoregional and distant disease, thereby expediting …

us (code pays fourni par la source)

Artificial Intelligence Model Using PSMA PET Imaging of Primary Prostate Cancer for Analyzing Metastases and Post-Treatment Progression

Jesus Eduardo Juarez, Cecil Mayra Benitez, Kamil Rzechowski, Karl Sjöstrand et autres

Incidental CT findings from myocardial perfusion PET/CTs

Gholam Reza Berenji, Cesar Puente, Katelyn Niknam, Richard Packard

Abstract Introduction New state-of-art hybrid imaging systems provide high quality CT images along with myocardial perfusion imaging (MPI), which introduces new opportunities and challenges for interpreting and referring physicians. American and European societies recommend reporting these CT scans including non MPI related …

us (code pays fourni par la source)

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

Nicholas George Nickols, Sonny Tsai, Nathanael Kane, Samantha Tran et autres

us (code pays fourni par la source)

Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.

Nicholas George Nickols, Sonny Tsai, Nathanael Kane, Silvia V. Diaz-Perez et autres

163 Background: Treatment paradigms for oligometastatic castration-sensitive prostate cancer patients are evolving. Molecular imaging improves staging, intensified systemic and primary tumor directed therapy improves survival, metastasis-directed therapy improves local control. The impact of combining these imaging and therapeutic approaches into a planned …

us (code pays fourni par la source)

Updated automated PROMISE assessment: Treatment response evaluation based on PSMA PET/CT.

Cecil Mayra Benitez, Hannicka Sahlstedt, Johan Brynolfsson, Gholam Reza Berenji et autres

48 Background: PSMA PETs can track treatment response in patients with prostate cancer. Recent integration of the RECIP framework with PROMISE v2 allows quantitative assessment of PSMA PETs. While useful for assessing differentially responding lesions, manual measurement and tracking is cumbersome and …

us (code pays fourni par la source)

A convolutional neural network model using intraprostatic patterns of [F18]DCFPyL uptake in PSMA PET images to predict synchronous metastases.

Jesus Eduardo Juarez, Cecil Mayra Benitez, Kamil Rzechowski, Karl Sjöstrand et autres

46 Background: [F18]DCFPyL (PyL) is a PSMA targeted imaging agent that provides whole-body staging of prostate cancer. Image analysis of the primary tumor using deep learning algorithms might offer additional insight into disease biology, including co-existing metastatic disease. We developed convolutional neural …

us (code pays fourni par la source)